# Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

> **NCT02719379** · PHASE1 · COMPLETED · sponsor: **Rohit Divekar** · enrollment: 60 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)

## Key facts

- **NCT ID:** NCT02719379
- **Lead sponsor:** Rohit Divekar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719379, "Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02719379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*